A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics
and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2 expressing or
mutated advanced malignant solid tumor subjects.